Cargando…

Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector

Intramuscular vaccination of mice with the naked pBI-11 DNA plasmid targeting E6 and E7 of HPV16 and HPV18 via a conventional syringe and needle generates human papillomavirus (HPV) antigen-specific CD8+ T cell-mediated immune responses and therapeutic effects against the TC-1 tumor model. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Shiwen, Tu, Hsin-Fang, Cheng, Michelle, Hu, Ming-Hung, Tsai, Hua-Ling, Tsai, Ya-Chea, Koenig, Chelsea, Brayton, Cory, Wang, Hao, Chang, Yung-Nien, Arend, Rebecca C., Levinson, Kimberly, Roden, Richard B. S., Wu, T. C., Hung, Chien-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653862/
https://www.ncbi.nlm.nih.gov/pubmed/37791765
http://dx.doi.org/10.1128/mbio.02121-23
_version_ 1785136504373248000
author Peng, Shiwen
Tu, Hsin-Fang
Cheng, Michelle
Hu, Ming-Hung
Tsai, Hua-Ling
Tsai, Ya-Chea
Koenig, Chelsea
Brayton, Cory
Wang, Hao
Chang, Yung-Nien
Arend, Rebecca C.
Levinson, Kimberly
Roden, Richard B. S.
Wu, T. C.
Hung, Chien-Fu
author_facet Peng, Shiwen
Tu, Hsin-Fang
Cheng, Michelle
Hu, Ming-Hung
Tsai, Hua-Ling
Tsai, Ya-Chea
Koenig, Chelsea
Brayton, Cory
Wang, Hao
Chang, Yung-Nien
Arend, Rebecca C.
Levinson, Kimberly
Roden, Richard B. S.
Wu, T. C.
Hung, Chien-Fu
author_sort Peng, Shiwen
collection PubMed
description Intramuscular vaccination of mice with the naked pBI-11 DNA plasmid targeting E6 and E7 of HPV16 and HPV18 via a conventional syringe and needle generates human papillomavirus (HPV) antigen-specific CD8+ T cell-mediated immune responses and therapeutic effects against the TC-1 tumor model. However, delivery of DNA vaccines by this method is less effective in patients, likely due to poor transduction of host tissues. Needle-free biojectors show great promise for DNA vaccination because of their simplicity of administration and high patient acceptability and also, we hypothesize, because of greater efficiency of cell transduction in host tissues. Here, we compared the kinetics of transgene expression from a plasmid DNA using intramuscular injection with a conventional needle administration to intradermal or intramuscular delivery with a customized Tropis biojector. Delivery using the customized Tropis biojector leads to enhanced transgene expression compared to intramuscular needle injection. In addition, we characterized the HPV antigen-specific CD8+ T cell-mediated immune responses and anti-tumor effects generated by pBI-11 DNA vaccination by each route of administration, as well as by split-dose multi-site injection. Intradermal, but not intramuscular, vaccination with pBI-11 DNA vaccine via customized Tropis biojector enhanced HPV antigen-specific CD8+ T cell-mediated immune responses over needle injection. Intradermal, but not intramuscular, vaccination via customized needle-free Tropis biojector elicited greater HPV antigen-specific CD8+ T cell-mediated immune responses as well as anti-tumor effects compared to intramuscular injection of pBI-11 with a needle. Good manufacturing practices (GMP) grade pBI-11 DNA vaccine delivered intradermally or intramuscularly via customized Tropis biojector was well tolerated by mice. IMPORTANCE: Respectively, HPV16 and HPV18 cause 50% and 20% of cervical cancer cases globally. Viral proteins E6 and E7 are obligate drivers of oncogenic transformation. We recently developed a candidate therapeutic DNA vaccine, pBI-11, that targets HPV16 and HPV18 E6 and E7. Single-site intramuscular delivery of pBI-11 via a needle elicited therapeutic anti-tumor effects in mice and is now being tested in high-risk human papillomavirus+ head and neck cancer patients (NCT05799144). Needle-free biojectors such as the Tropis device show promise due to ease of administration, high patient acceptability, and the possibility of improved delivery. For example, vaccination of patients with the ZyCoV-D DNA vaccine using the Tropis device is effective against COVID19, well tolerated, and licensed. Here we show that split-dose, multi-site administration and intradermal delivery via the Tropis biojector increase the delivery of pBI-11 DNA vaccine, enhance HPV antigen-specific CD8+ T-cell responses, and improve anti-tumor therapeutic effects, suggesting its translational potential to treat HPV16/18 infection and disease.
format Online
Article
Text
id pubmed-10653862
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-106538622023-10-04 Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector Peng, Shiwen Tu, Hsin-Fang Cheng, Michelle Hu, Ming-Hung Tsai, Hua-Ling Tsai, Ya-Chea Koenig, Chelsea Brayton, Cory Wang, Hao Chang, Yung-Nien Arend, Rebecca C. Levinson, Kimberly Roden, Richard B. S. Wu, T. C. Hung, Chien-Fu mBio Research Article Intramuscular vaccination of mice with the naked pBI-11 DNA plasmid targeting E6 and E7 of HPV16 and HPV18 via a conventional syringe and needle generates human papillomavirus (HPV) antigen-specific CD8+ T cell-mediated immune responses and therapeutic effects against the TC-1 tumor model. However, delivery of DNA vaccines by this method is less effective in patients, likely due to poor transduction of host tissues. Needle-free biojectors show great promise for DNA vaccination because of their simplicity of administration and high patient acceptability and also, we hypothesize, because of greater efficiency of cell transduction in host tissues. Here, we compared the kinetics of transgene expression from a plasmid DNA using intramuscular injection with a conventional needle administration to intradermal or intramuscular delivery with a customized Tropis biojector. Delivery using the customized Tropis biojector leads to enhanced transgene expression compared to intramuscular needle injection. In addition, we characterized the HPV antigen-specific CD8+ T cell-mediated immune responses and anti-tumor effects generated by pBI-11 DNA vaccination by each route of administration, as well as by split-dose multi-site injection. Intradermal, but not intramuscular, vaccination with pBI-11 DNA vaccine via customized Tropis biojector enhanced HPV antigen-specific CD8+ T cell-mediated immune responses over needle injection. Intradermal, but not intramuscular, vaccination via customized needle-free Tropis biojector elicited greater HPV antigen-specific CD8+ T cell-mediated immune responses as well as anti-tumor effects compared to intramuscular injection of pBI-11 with a needle. Good manufacturing practices (GMP) grade pBI-11 DNA vaccine delivered intradermally or intramuscularly via customized Tropis biojector was well tolerated by mice. IMPORTANCE: Respectively, HPV16 and HPV18 cause 50% and 20% of cervical cancer cases globally. Viral proteins E6 and E7 are obligate drivers of oncogenic transformation. We recently developed a candidate therapeutic DNA vaccine, pBI-11, that targets HPV16 and HPV18 E6 and E7. Single-site intramuscular delivery of pBI-11 via a needle elicited therapeutic anti-tumor effects in mice and is now being tested in high-risk human papillomavirus+ head and neck cancer patients (NCT05799144). Needle-free biojectors such as the Tropis device show promise due to ease of administration, high patient acceptability, and the possibility of improved delivery. For example, vaccination of patients with the ZyCoV-D DNA vaccine using the Tropis device is effective against COVID19, well tolerated, and licensed. Here we show that split-dose, multi-site administration and intradermal delivery via the Tropis biojector increase the delivery of pBI-11 DNA vaccine, enhance HPV antigen-specific CD8+ T-cell responses, and improve anti-tumor therapeutic effects, suggesting its translational potential to treat HPV16/18 infection and disease. American Society for Microbiology 2023-10-04 /pmc/articles/PMC10653862/ /pubmed/37791765 http://dx.doi.org/10.1128/mbio.02121-23 Text en Copyright © 2023 Peng et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Article
Peng, Shiwen
Tu, Hsin-Fang
Cheng, Michelle
Hu, Ming-Hung
Tsai, Hua-Ling
Tsai, Ya-Chea
Koenig, Chelsea
Brayton, Cory
Wang, Hao
Chang, Yung-Nien
Arend, Rebecca C.
Levinson, Kimberly
Roden, Richard B. S.
Wu, T. C.
Hung, Chien-Fu
Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title_full Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title_fullStr Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title_full_unstemmed Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title_short Immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic HPV16/18 E6/E7 DNA vaccination via needle-free biojector
title_sort immune responses, therapeutic anti-tumor effects, and tolerability upon therapeutic hpv16/18 e6/e7 dna vaccination via needle-free biojector
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653862/
https://www.ncbi.nlm.nih.gov/pubmed/37791765
http://dx.doi.org/10.1128/mbio.02121-23
work_keys_str_mv AT pengshiwen immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT tuhsinfang immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT chengmichelle immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT huminghung immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT tsaihualing immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT tsaiyachea immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT koenigchelsea immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT braytoncory immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT wanghao immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT changyungnien immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT arendrebeccac immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT levinsonkimberly immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT rodenrichardbs immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT wutc immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector
AT hungchienfu immuneresponsestherapeuticantitumoreffectsandtolerabilityupontherapeutichpv1618e6e7dnavaccinationvianeedlefreebiojector